Nukkleus Inc. (NASDAQ:DFNS – Get Free Report) was the target of a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 489,971 shares, an increase of 77.3% from the September 30th total of 276,275 shares. Based on an average daily volume of 691,705 shares, the short-interest ratio is currently 0.7 days. Currently, 33.1% of the shares of the company are short sold.
Analyst Upgrades and Downgrades
DFNS has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nukkleus in a report on Friday, October 16th. Wall Street Zen cut Nukkleus from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 5th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.
Nukkleus Trading Down 5.0%
Nukkleus (NASDAQ:DFNS – Get Free Report) last posted its quarterly earnings data on Wednesday, August 19th. The company reported ($173.80) EPS for the quarter, missing the consensus estimate of ($3.11) by ($170.69). The firm had revenue of $4.00 million during the quarter, compared to analysts’ expectations of $4.50 million. As a group, equities analysts anticipate that Nukkleus will post -3.90 earnings per share for the current year.
Nukkleus Company Profile
Nukkleus, Inc is a technology-focused holding company that has historically developed and operated digital infrastructure for the financial-services industry. Its activities have included software and services supporting electronic trading, foreign-exchange brokerage operations, payments, risk management and digital-asset transactions.
The company’s financial-technology portfolio has included platforms and tools designed to help brokers and other financial institutions manage trading operations, liquidity, client relationships and related back-office functions.
Further Reading
- Five stocks we like better than Nukkleus
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
Receive News & Ratings for Nukkleus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nukkleus and related companies with MarketBeat.com's FREE daily email newsletter.
